TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
| Website: | www.tgtherapeutics.com |
| Email: | ir@tgtxinc.com |
| Main Phone: | +1 212 554-4484 |
| Address: | 2 Gansevoort Street |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10014 |
| Exchange: | NSC |
| CEO: | Michael S. Weiss |
| Employees: | 102 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Gathering Data... Please wait TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.
| Website: | www.tgtherapeutics.com |
| Email: | ir@tgtxinc.com |
| Main Phone: | +1 212 554-4484 |
| Address: | 2 Gansevoort Street |
| Address 2: | 9th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | USA |
| Postal Code: | 10014 |
| Exchange: | NSC |
| CEO: | Michael S. Weiss |
| Employees: | 102 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 7.74 | Change $ -0.23 | Change % -2.89 | Tick N/A |
| Bid 7.50 | Bid Size 1,300.00 | Ask 8.11 | Ask Size 200.00 |
| Open 7.97 | High 7.98 | Low 7.74 | Prev Close 7.97 |
| Last Trade | Volume 972,367 | 52 Wk Hi 12.90 | 52 Wk Low 3.32 |
| Market Cap 703.1 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 90,835,329.00 | EPS (TTM) -2.14 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 12 |
| Number of Buys | 0 | 8 |
| Number of Sells | 0 | 4 |
| Net Activity | 0 | 552895 |
| Last 10 Buys | Shares |
|---|---|
| Michael S. Weiss | 1,000 |
| Neil Herskowitz | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Michael S. Weiss | 1,000 |
| Michael S. Weiss | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| William J. Kennedy | 1,000 |
| Laurence N. Charney | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| Sean A. Power | 1,000 |
| William J. Kennedy | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 38 | 38 | 38 | 38 |
| Low Target Price Estimate | 22 | 22 | 22 | 22 |
| Mean Target Price Estimate | 29.67 | 29.67 | 29.67 | 29.67 |
| Standard Deviation | 7.34 | 7.34 | 7.34 | 7.34 |
| Date of Most Recent Estimate | 06/04/18 | 05/25/18 | 05/11/18 | 06/04/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-13 |
| 8-K | Report of unscheduled material events or corporate changes. | 24 | 2018-06-07 |
| 8-K | Report of unscheduled material events or corporate changes. | 13 | 2018-06-04 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 54 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-05-08 |
| CT ORDER | 1 | 2018-04-30 | |
| DEFA14A | Additional proxy soliciting materials - definitive | 5 | 2018-04-30 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 49 | 2018-04-30 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-04-24 |
| 10-K | Annual report with a comprehensive overview of the company | 141 | 2018-03-15 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
